Tag: Pfizer
Pfizer to acquire Biohaven in $11.6bn deal to gain access to rimegepant
Pfizer has agreed to acquire Biohaven Pharmaceutical, a US-based biopharma company, in a deal worth around $11.6 billion, to gain access to the latter’s dual-acting ... Read More
Pfizer RSVpreF vaccine candidate gets another FDA breakthrough therapy status
Pfizer said that PF-06928316 (RSVpreF), its respiratory syncytial virus (RSV) vaccine candidate, has been granted breakthrough therapy designation from the US Food and Drug Administration ... Read More
Torrent Pharmaceuticals gets rights to generic of Pfizer’s oral Covid-19 treatment
Torrent Pharmaceuticals has entered into a licensing agreement with Medicine Patent Pool (MPP) for manufacturing and commercializing the generic version of Pfizer’s oral Covid-19 treatment. ... Read More
SMS Pharmaceuticals gets license to Pfizer Covid‐19 drug nirmatrelvir
SMS Pharmaceuticals has secured a non‐exclusive license via the Medicines Patent Pool (MPP) for manufacturing nirmatrelvir, an oral antiviral Covid‐19 drug developed by Pfizer, to ... Read More
Pfizer gets FDA breakthrough status for RSVpreF RSV vaccine candidate
Pfizer has secured breakthrough therapy designation for its respiratory syncytial virus (RSV) vaccine candidate — PF-06928316 (RSVpreF) from the US Food and Drug Administration (FDA) ... Read More
Alembic Pharmaceuticals gets FDA approval for Toviaz generic
Alembic Pharmaceuticals said that it has secured tentative approval from the US Food & Drug Administration (FDA) for its abbreviated new drug application (ANDA) for ... Read More
Pfizer to acquire US biopharma company Arena Pharmaceuticals for $6.7bn
Pfizer has agreed to acquire Arena Pharmaceuticals, a publicly-listed clinical stage biopharma company based in the US, for about $6.7 billion. As per the terms ... Read More
Pfizer to acquire immuno-oncology company Trillium Therapeutics for $2.2bn
US pharma giant Pfizer has agreed to acquire Trillium Therapeutics, a publicly listed Canadian clinical stage immuno-oncology company, for $18.5 per share or $2.26 billion ... Read More
Vivet’s VTX-801 gene therapy gets FDA fast track status in Wilson Disease
Vivet Therapeutics, a biotech company backed by Pfizer, has been given fast track designation by the US Food and Drug Administration for its gene therapy ... Read More
Pfizer gets FDA approval for tick-borne encephalitis vaccine TICOVAC
Pfizer has secured approval for its TICOVAC vaccine from the US Food and Drug Administration (FDA) for active immunization against tick-borne encephalitis (TBE) in individuals ... Read More